If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Prozac And Group Therapy Effective For HIV-Positive Patients With Depression SAN DIEGO, CA -- May 28, 1998 -- A study published in today’s issue of the Journal of Clinical Psychiatry demonstrates that Prozac (fluoxetine hydrochloride) in combination with group therapy is more effective than group therapy alone in treating HIV-positive patients diagnosed with major depression. The study, among the first to compare the effectiveness of selective serotonin re-uptake inhibitor antidepressants like Prozac against psychotherapy, also shows that Prozac did not interact significantly with any HIV medications and produced minimal side effects. Results of the study might lead to better compliance by patients already taking multiple drug therapies, according to Sidney Zisook, M.D., professor of psychiatry with University of California-San Diego School of Medicine and lead author of the study. Major depressive episodes are estimated to be present in seven to 20 percent of all HIV-positive patients. HIV patients often suffer multiple medical complications and tend to receive a number of potentially-toxic medications during the course of their illness. "They can ill afford to receive yet another medication unless the treatment is safe," Zisook said. The randomised, double blind, placebo-controlled study examined 47 HIV positive men who were seen in weekly supportive group therapy. The sample consisted of men who had recurrent major depression and whose present episode had been continuing for at least several months. On average, patients had been HIV positive for about three years prior to entry into the study. Twenty-five patients were given up to 60 mg of Prozac during the seven week trial. Twenty-two patients received a placebo. Researchers found statistically-significant differences favouring group psychotherapy plus Prozac over group psychotherapy plus placebo. Patients treated with Prozac experienced a two-fold improvement in baseline depression rating scales (12.1 for subjects given Prozac versus 6.6 for subjects given the placebo). A greater percentage of patients in the Prozac group (64 percent versus 23 percent) experienced a reduction of at least 50 percent in depression rating scores. Similarly, the percentage of patients who were rated as either very much improved or much improved was higher (64 percent versus 48 percent) in the Prozac group. Among patients rated as severely depressed, those treated with psychotherapy plus Prozac appeared to do significantly better than those treated with psychotherapy and placebo. Patients rated as mild to moderately depressed appeared to do equally well whether treated with psychotherapy and Prozac or psychotherapy and placebo. "As the HIV epidemic continues to spread world wide, more HIV positive men and women with depression can expect to require treatment," Dr. Zisook said. "Patients who are HIV positive and experience depression can and do respond to antidepressant treatment." Factors that may contribute to the onset of a major depression in patients with HIV include isolation from social supports, occupational disability, alterations in body image, bereavement, loss of friends, debilitation, effects of HIV virus on the brain and the knowledge of having a terminal illness. Although patients were taking antiretroviral agents such as AZT, the study was completed before the widespread use of protease inhibitors. No serious drug interactions involving the combination of protease inhibitors and SSRIs have been reported. However, the potential for drug interactions does exist. Since all patients were treated with group psychotherapy, the study is not considered a true placebo study. Several smaller studies have supported the effectiveness of group psychotherapy for treating HIV-associated depression. More information on: Prozac.
|
